Dyax Corp. Company Profile (NASDAQ:DYAX)

About Dyax Corp.

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DYAX
  • CUSIP: 26746E10
Key Metrics:
  • Previous Close: $38.41
  • 50 Day Moving Average: $37.73
  • 200 Day Moving Average: $29.05
  • 52-Week Range: $14.06 - $38.56
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -274.36
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Dyax Corp.:

Analyst Ratings

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $37.00 (3.67% downside)

Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetDetails
12/7/2015Royal Bank Of CanadaReiterated RatingBuyView Rating Details
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00View Rating Details
11/5/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details
11/2/2015Jefferies GroupDowngradeBuy -> Hold$37.00View Rating Details
11/2/2015WedbushDowngradeOutperform -> NeutralView Rating Details
5/11/2015Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$26.00View Rating Details
4/1/2015Bank of America Corp.Boost Price TargetBuy$16.00 -> $30.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2016        
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014($0.05)($0.05)ViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
10/22/2013Q313($0.05)($0.06)$14.80 million$13.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.03)($0.03)($0.03)
Q4 20162($0.01)$0.01$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
DateHeadline
News IconBusiness Briefs - Your Houston News (NASDAQ:DYAX)
www.yourhoustonnews.com - September 26 at 4:53 PM
istreetwire.com logoStocks To Watch: Marathon Petroleum Corporation (MPC), Merrimack Pharmaceuticals, Inc. (MACK), J. C. Penney ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - September 26 at 9:26 AM
istreetwire.com logoEye Catching Stocks: Merrimack Pharmaceuticals, Inc. (MACK), J. C. Penney Company, Inc. (JCP), Kinder Morgan, Inc ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - September 24 at 9:21 AM
News IconBayh reflects on return to the fray: Former governor faces Todd Young in November - Vincennes Sun Commercial (NASDAQ:DYAX)
www.suncommercial.com - September 24 at 9:21 AM
News IconBayh reflects on return to the fray - Evening News and Tribune (NASDAQ:DYAX)
www.newsandtribune.com - September 21 at 5:13 PM
News IconBayh reflects on return to the fray (NASDAQ:DYAX)
www.newsandtribune.com - September 21 at 9:01 AM
News IconBayh reflects on return to the fray - Kokomo Tribune (NASDAQ:DYAX)
www.kokomotribune.com - September 19 at 9:23 AM
4-traders.com logoShire : District Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA® (NASDAQ:DYAX)
www.4-traders.com - September 17 at 9:26 AM
News IconDyax Corp. - Medical Equipment - Deals and Alliances Profile - New Report Available (NASDAQ:DYAX)
reports.pr-inside.com - September 13 at 9:37 AM
News IconNext Generation Antibody Therapeutics Market with steady growth at a CAGR of 13.0% by 2022 - Medgadget (blog) (NASDAQ:DYAX)
www.medgadget.com - September 9 at 4:34 PM
News IconPlacing Dyax Corp. (NASDAQ:DYAX) Shares Under the Microscope - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - September 8 at 8:34 AM
finance.yahoo.com logoSanthera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts ... - Yahoo Finance (NASDAQ:DYAX)
finance.yahoo.com - September 7 at 8:02 AM
finanznachrichten.de logoSANTHERA PHARMACEUTICALS HOLDING AG (NASDAQ:DYAX)
www.finanznachrichten.de - September 6 at 9:34 AM
benzinga.com logoSanthera Announces Financial Results for the... (NASDAQ:DYAX)
www.benzinga.com - September 6 at 9:34 AM
4-traders.com logoShire : U.S. Securities and Exchange Commission filings (NASDAQ:DYAX)
www.4-traders.com - September 5 at 9:21 AM
News IconStock in Review: Taking a Closer Look at Dyax Corp. (NASDAQ:DYAX) Shares - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - September 1 at 8:31 AM
istreetwire.com logoStocks To Watch: Merrimack Pharmaceuticals, Inc. (MACK), Catalent, Inc. (CTLT), LaSalle Hotel Properties (LHO) - iStreetWire (NASDAQ:DYAX)
istreetwire.com - August 31 at 9:33 AM
mysmartrend.com logoShares of DYAX Up 59.4% Since Uptrend Call on Shares (NASDAQ:DYAX)
www.mysmartrend.com - August 30 at 4:48 PM
News IconBBergCV.2015.12 (NASDAQ:DYAX)
www.slideshare.net - August 29 at 8:52 PM
News IconShire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% is Now Available in the U.S. (NASDAQ:DYAX)
www.presseportal.de - August 29 at 3:45 PM
News IconIs it Time to Buy Dyax Corp. (NASDAQ:DYAX)? The Consensus Is In - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - August 25 at 4:46 PM
News IconShire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye (NASDAQ:DYAX)
www.presseportal.de - August 25 at 9:41 AM
News IconSell-side & Crowd View on Dyax Corp. (NASDAQ:DYAX) - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - August 20 at 8:10 AM
istreetwire.com logoStocks on the Move: Intrexon Corporation (XON), Waste Management, Inc. (WM), Merrimack Pharmaceuticals, Inc ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - August 18 at 4:47 PM
News IconCan Earnings Grow for Dyax Corp. (NASDAQ:DYAX)? - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - August 18 at 4:47 PM
News IconCrowd & Street Analysis on Dyax Corp. (NASDAQ:DYAX) - Post News (NASDAQ:DYAX)
www.kentuckypostnews.com - August 18 at 7:34 AM
istreetwire.com logoStocks Buzz: U.S. Silica (SLCA), Merrimack Pharmaceuticals (MACK) Prologis (PLD) - iStreetWire (NASDAQ:DYAX)
istreetwire.com - August 11 at 4:51 PM
ftsenews.co.uk logoNew Broker Ratings For Dyax Corp. (DYAX) - FTSE News (NASDAQ:DYAX)
www.ftsenews.co.uk - August 10 at 11:58 AM
4-traders.com logoShire : VONVENDI, The First and Only Recombinant Treatment for Adults Affected by Von Willebrand Disease, Launches in the U.S. (NASDAQ:DYAX)
www.4-traders.com - August 9 at 7:58 AM
istreetwire.com logoStocks Trend Analysis: CBRE Group, Inc. (CBG) Merrimack Pharmaceuticals, Inc. (MACK) Dick's Sporting Goods Inc ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - August 5 at 8:29 AM
ftsenews.co.uk logoDyax Corp. (DYAX) Updated Price Targets - FTSE News (NASDAQ:DYAX)
www.ftsenews.co.uk - August 5 at 8:29 AM
News IconHot Stock's Alert: Liberty Global plc – Class A Ordinary Shares ... - NYSE Journal (press release) (NASDAQ:DYAX)
stockznews.com - August 4 at 8:01 AM
News IconShire on track for $20b in sales by 2020 (NASDAQ:DYAX)
www.bostonglobe.com - August 2 at 4:53 PM
prnewswire.com logoShire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook - PR Newswire (press release) (NASDAQ:DYAX)
www.prnewswire.com - August 2 at 9:33 AM
News IconShire chief says drug maker on track for $20 billion in sales by 2020 - The Boston Globe (NASDAQ:DYAX)
www.bostonglobe.com - August 2 at 9:33 AM
marketrealist.com logoHow Will Shire's ADHD Franchise Perform in 2Q16? - Market Realist (NASDAQ:DYAX)
marketrealist.com - July 27 at 10:26 PM
4-traders.com logoShire : ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia (NASDAQ:DYAX)
www.4-traders.com - July 26 at 8:52 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Dyax Corp. (NASDAQ:DYAX) - TGP (NASDAQ:DYAX)
telanaganapress.com - July 21 at 8:13 AM
News IconDyax Corp. (NASDAQ:DYAX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:DYAX)
www.engelwooddaily.com - July 20 at 8:11 AM
News IconTrading Performance and Target Watch for Dyax Corp. (NASDAQ:DYAX) - Press Telegraph (NASDAQ:DYAX)
presstelegraph.com - July 18 at 4:51 PM
News IconBurlington Sends Mixed Signals - Banker & Tradesman (NASDAQ:DYAX)
www.bankerandtradesman.com - July 17 at 4:26 PM
News IconBurlington Sends Mixed Signals (NASDAQ:DYAX)
www.bankerandtradesman.com - July 17 at 9:15 AM
News IconCrowd Rating and Earnings Recap for Dyax Corp. (NASDAQ:DYAX) - Telanagana Press (NASDAQ:DYAX)
telanaganapress.com - July 15 at 11:57 AM
istreetwire.com logoThree Movers to Watch for: RSP Permian, Inc. (RSPP), ZIOPHARM Oncology, Inc. (ZIOP), Merrimack Pharmaceuticals ... - iStreetWire (NASDAQ:DYAX)
istreetwire.com - July 14 at 4:22 PM
thestreet.com logoShire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta - TheStreet.com (NASDAQ:DYAX)
www.thestreet.com - July 14 at 4:22 PM
fiscalstandard.com logoDyax Corp. (DYAX) Current Analyst Ratings - Fiscal Standard (NASDAQ:DYAX)
www.fiscalstandard.com - July 13 at 9:59 PM
News IconDyax Corp. (NASDAQ:DYAX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:DYAX)
www.engelwooddaily.com - July 13 at 8:57 AM
News IconDrug-Induced Angioedema (NASDAQ:DYAX)
www.medscape.com - July 10 at 4:31 PM
News IconDrug-Induced Angioedema - Medscape (NASDAQ:DYAX)
www.medscape.com - July 8 at 4:43 PM
News IconGlobal Breast Cancer Monoclonal Antibodies Market 2016- Amgen, Biocad, Biocon, Celltrion Pharm, CuraGen ... - cHollywood News Portal (press release) (NASDAQ:DYAX)
chollywood.info - July 6 at 4:48 PM

Social

Dyax Corp. (NASDAQ:DYAX) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff